For how fibrosis screening connects to therapy decisions, see MASH treatment: resmetirom, semaglutide, and MASLD care.Summary: MASLD screening is the process of finding people with fatty liver who may already have significant fibrosis or who need closer follow-up. The key point is that liver fat itself is common, but liver fibrosis is the feature most strongly tied to future cirrhosis, liver cancer, and liver-related outcomes.
Metabolic dysfunction-associated steatotic liver disease, or MASLD, is closely linked to obesity, insulin resistance, prediabetes, type 2 diabetes, high triglycerides, hypertension, and metabolic syndrome. Many people have no symptoms. ALT may be normal even when risk is present. A structured screening pathway helps separate low-risk fatty liver from possible advanced fibrosis.
FIB-4 is a simple fibrosis risk score calculated from age, AST, ALT, and platelet count. It is not a diagnosis of fibrosis. It is a triage tool. A low-risk FIB-4 can often reassure clinicians, while an indeterminate or elevated FIB-4 should lead to second-step testing or referral depending on the clinical situation.
FIB-4 is especially useful in people with type 2 diabetes, obesity, metabolic syndrome, or unexplained liver enzyme abnormalities because these groups have higher MASLD fibrosis risk.
When FIB-4 is elevated or indeterminate, guidelines commonly use liver stiffness measurement, such as vibration-controlled transient elastography, as a second step. Liver stiffness helps estimate fibrosis risk more directly than routine liver enzymes.
This two-step model is important for primary care because it avoids sending every person with fatty liver to specialty care while still identifying people who need further evaluation.
MASLD screening has become more important because treatments and risk-based pathways are improving. The 2026 ADA Standards of Care discuss risk stratification with FIB-4 followed by liver stiffness measurement when FIB-4 is elevated. The same section discusses GLP-1 receptor agonists, tirzepatide data, and resmetirom for selected adults with noncirrhotic MASH and F2-F3 fibrosis.
MASLD screening is not about alarming every person with liver fat. It is about finding fibrosis risk early. FIB-4 and liver stiffness measurement give clinicians a practical pathway from routine labs to risk-based care.
Sources: ADA, Standards of Care in Diabetes 2026, MASLD assessment and treatment section; Internets FIB-4 clinical resource.
Fatty Liver Disease (MASLD) • MASLD Explained Simply • De Novo Lipogenesis • CKM Syndrome
© 2026 Internets. All rights reserved.